Skip to main content

Chronic Lymphocytic Leukemia Excellence Forum

News
Overall survival in patients with chronic myeloid leukemia appears to vary widely depending on where the patient lives, according to a poster from the 2020 ASCO Virtual Scientific Program. The finding stemmed from an investigation into cancer outcomes for…
News
Researchers of a recent study examined a significant shift in the treatment patterns for patients with chronic lymphocytic leukemia (CLL) in the Veterans Health Administration (VHA) but note that more research is needed to understand the impact on health care…
News
In a rare case of ocular relapse in a patient with chronic lymphocytic leukemia (CLL), the oral Bruton tyrosine kinase inhibitor, Imbruvica (ibrutinib) proved to be a safe and effective treatment, according to a recent study. “This case represents a rare…
News
In a recent study, researchers examined the outcomes of patients with chronic lymphocytic leukemia (CLL) treated with CD19-specific Chimeric antigen receptor T-cell (CAR-T) therapy—specifically focusing on overall survival and progression following CART-T…
Video
Lindsey Roeker, MD, physician, Memorial Sloan Kettering Cancer Center, comments on the thought process behind the decision to use specialty medications in the treatment of chronic lymphocytic leukemia.   Read More: The Latest in HEOR First Report…
News
Researchers recently studied the influence genetics have on chronic lymphocytic leukemia (CLL) patients’ response to anti-CD19 chimeric antigen receptor (CAR)-T cell therapy. Veronika Mancikova, PhD, Central European Institute of Technology (CEITEC), Masaryk…
News
Single-agent ibrutinib was found to have both sustained responses and long-term tolerability for the treatment of first-line or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), according to a study published in Clinical…
Video
Lindsey Roeker, MD, physician, Memorial Sloan Kettering Cancer Center, breaks down the treatment landscape and disease burden commonly faced among patients with chronic lymphocytic lymphoma.   
Back to Top